2A Pharma

Executive Summary

2A Pharma is a clinical-stage biopharmaceutical company based in Stockholm, Sweden, founded in 2015. The company specializes in developing prophylactic and therapeutic vaccines using its proprietary adeno-associated virus-like particle (AAVLP) platform, which aims to address incurable diseases in immuno-oncology and autoimmune indications. The platform leverages the immunogenic properties of AAV capsids to elicit robust B-cell and T-cell responses without the risks associated with live viral vectors. The company's lead candidate, AAVLP-HPV, targets papillomavirus infections and completed a Phase 1 clinical trial (NCT03929172) in 2020. With this proof-of-concept data, 2A Pharma is poised to advance its pipeline into later-stage trials and explore additional indications. The platform's versatility suggests potential for rapid expansion into other infectious diseases and cancer vaccines. However, the company remains in early stages with no disclosed funding or partnerships, making its trajectory uncertain.

Upcoming Catalysts (preview)

• Q2 2027Initiation of Phase 2 trial for AAVLP-HPV50% success
• Q4 2026New platform partnership or licensing deal30% success
• Q3 2026Preclinical data for second AAVLP candidate (e.g., oncology)40% success